Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

Conference Call to Discuss Results On Thursday, March 29, 2007, At 2:00 p.m. Pacific Time

SAN DIEGO, March 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS).

The randomized, double-blind, placebo-controlled trial showed a significant increase in the proportion of patients who remained relapse-free over the first 12 months of treatment with 60 mg per day of MN-166 compared to placebo (p=0.03). The time to first relapse was also significantly increased in patients treated with 60 mg of MN-166 per day compared to placebo (p=0.04). Positive trends were also observed in the annualized relapse rate (p=0.08) and number of relapses (p=0.10) among patients who completed the full first 12 months of treatment with 60 mg of MN-166 per day compared to those patients completing the first 12 months of treatment on placebo.

A significant reduction in brain volume loss (p=0.04), as measured by cranial magnetic resonance imaging (MRI) scans, was observed in patients treated with 60 mg per day of MN-166 compared to placebo. Loss of brain volume on MRI has been shown to correlate with clinical progression and disability in MS patients. Positive trends were also observed in several other radiological outcome measures, including the volume of gadolinium-enhancing (T1) lesions (p=0.09) in patients treated with 60 mg of MN-166 per day compared with placebo. However, no reduction in the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlarging (T2)) lesions on crani
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/22/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... with operations in China and ... will release financial results for the second quarter of 2014 ... 13, 2014 (which will be Thursday morning, August 14, 2014 ... investor relations section of the Company,s website at http://www.wuxiapptec.com ...
(Date:7/22/2014)... EASTON, Mass. , July 22, 2014 ... or the "Company") and Parabase Genomics ("Parabase"), ... entered into a strategic research and development ... the collaboration, PBI will develop a front-end, ... molecular diagnostics and newborn confirmatory testing process. ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... , MEXICO CITY, December 9 ... SNY),announced today the expansion of its dengue vaccine clinical program ... in Mexico,Colombia, Honduras and Puerto Rico. This new multicenter study complements ... These studies are aimed at advancing the ...
... , CHICAGO, Dec. 9 Uniting the world,s most ... university-based research teams utilizing a coordinated and "wired" approach ... most innovative partnership of its kind. , ... today announced a collaboration that includes the State of ...
Cached Medicine Technology:Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5
(Date:7/22/2014)... The Pennsylvania judge overseeing hundreds ... in the Philadelphia Court of Common Pleas won’t ... cases alleging the medication caused plaintiffs to develop ... In an Order dated July 18, 2014, Judge ... certify the matter for an immediate appeal to ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... minimally invasive procedure known as morcellation carries a risk of ... likelihood more clearly. Twenty-seven of every 10,000 women who ... of the procedure, researchers found, with the odds being highest ... a hysterectomy with morcellation use a power cutter to slice ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 According to ... Health care, Automobile, Aerospace & Defense, Marine and Mining) ... Middle East, and Rest of the world) - Forecast ... is expected to grow at a CAGR 8.00% to ... Europe is estimated to grow at a CAGR of ...
(Date:7/22/2014)... Dimension One Spas’ retailers across the country are ... during the “Let’s Take This Outside” Summer Event from ... for more information and to apply. , As ... wide variety of outdoor hot tubs with exclusive features ... massage, and personal controls. , To find ...
(Date:7/22/2014)... News) -- People who suffer long-term sleep problems after ... blood pressure, a new study suggests. Previous research ... early death, but few studies have examined the reasons ... the causes, according to the University of Arizona investigators. ... separated or divorced for about 16 weeks. They reported ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2
... , FRIDAY, Nov. 11 (HealthDay News) -- Vaccination ... type b (Hib) among young children in the United States ... That strain of flu was once the most common cause ... mid-1980s. But the researchers also found that other strains ...
... (November 11, 2011) Children treated at home for severe ... recover than children referred to health facilities, Save the Children ... Lancet medical journal today. The results come the ... world,s attention on the leading cause of child death. ...
... University of Michigan researchers will provide genetic testing and ... mild cognitive impairment. Researchers hope to ... caregivers respond to health education and genetic testing, says ... Behavior and Health Education at the U-M School of ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... between the ages of 18 and 25 report the highest ... Survey on Drug Use & Health. A new study from ... in prosocial behaviors, such as volunteering and helping others, are ... Carlo, Millsap Professor of Diversity in the Department of Human ...
... Foundation (AHAF), a nonprofit organization funding innovative research through ... the number of scientists seeking ADR research grants through ... "It,s a sign of difficult times for the ... Guy Eakin, Ph.D. "Finding government funding is tough ...
Cached Medicine News:Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 2Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 3Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Volunteering, helping others decreases substance use in rural teens, MU study finds 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: